Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

37 results about "Contragestazol" patented technology

Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo

Application of miR-615 in ovarian granular cells

The invention relates to the technical field of molecular biology, and particularly discloses application of miR-615 in ovarian granular cells. The miR-615 is applied to any one of the following items: preparing a product for promoting the activity and / or proliferation of ovarian granular cells; preparing a product for promoting generation of estradiol and / or progesterone; preparing a product for promoting the expression of the 3 beta-HSD and / or StAR gene; preparing a product for inhibiting ACSL4 gene expression; and preparing a product competitively combined with the lnc-GAM. According to the invention, porcine ovarian granular cells are used as a material, the expression level of lnc-GAM-miR-615 / ACSL4 regulatory axis is up-regulated or down-regulated in the porcine ovarian granular cells by using gene overexpression and interference technologies, and the expression of the lnc-GAM-miR-615 / ACSL4 regulatory axis is determined by detecting cell proliferation activity, hormone secretion level and apoptosis gene expression in combination with a dual-luciferase reporter gene test. And the regulation effect of lnc-GAM mediation on the apoptosis of the porcine ovarian granular cells is researched.
Owner:INST OF ANIMAL HUSBANDRY & VETERINARY MEDICINE ANHUI ACAD OF AGRI SCI +1

Application of CTH inhibitor and / or xCT inhibitor in preparation of medicine for inhibiting mammalian embryo implantation

The invention provides an application of a CTH inhibitor and / or an xCT inhibitor in preparation of a medicine for inhibiting mammal embryo implantation, and relates to the technical field of medicines. The application effect of a cystathionine-gamma-lyase (CTH) inhibitor and / or a solute carrier family 7 member 11 (xCT) inhibitor in inhibition of mammalian embryo implantation is verified through research. The research result shows that the xCT inhibitor and / or the CTH inhibitor can obviously inhibit proliferation of corpus luteinized granular cells and secretion of progesterone of a model mouse; meanwhile, by injecting the xCT inhibitor and / or the CTH inhibitor into the mouse model in vivo, ovary ovulation and the maturation rate of the ovulated oocyte nucleus can be remarkably inhibited, functional corpus luteum formation and embryo implantation can be remarkably reduced, and then a new thought and method are provided for development of contraceptive drugs.
Owner:INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS

Use of a pharmaceutical composition for the preparation of a medicament for inhibiting implantation of a mammalian embryo

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.
Owner:INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS

A magnetic particle-based enzyme-catalyzed chemiluminescent immunoassay reagent for the detection of testosterone

ActiveCN113624982Bfast dissociationeffective dissociationBiological testingAntigenAntiendomysial antibodies
The present invention relates to the field of immunoassay technology, and specifically relates to a magnetic particle enzymatic chemiluminescent immunoassay reagent for testosterone. The present invention discloses a magnetic particle enzymatic chemiluminescent immunoassay reagent for testosterone, and its components include: 0.01-0.05% superparamagnetic particles coated with testosterone antigen, alkaline phosphatase labeled testosterone antibody, testosterone release reagent, alkaline phosphatase luminescent substrate and magnetic bead cleaning solution; the testosterone release reagent is one or more combinations of dihydrotestosterone, danazol, heparin sodium, 8-aniline-1-naphthalenesulfonic acid (ANS), 8-aniline-1-naphthalenesulfonate, sodium trichloroacetate, 2-Hydroxymethyleneethisterone (CAS: 2787-02-2), ethisterone (CAS: 434-03-7), and 2-Hydroxymethyl-1,2-dehydroethisterone (CAS: 60142-08-7).
Owner:SHENZHEN CHANNEL BIOTECHNOLOGY CO LTD

Chimeric polypeptides and methods of altering their localization in the cell membrane

Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Essentially, the protein must comprise, in addition to a transmembrane domain, also a hormone receptor like the estrogen receptor alpha or the progesterone receptor. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
Owner:CELL DESIGN LABS INC

A method for modeling, evaluating and application of an animal model of menstrual dysmenorrhea

The application relates to the technical field of animal models, in particular to a modeling method and an evaluation method of an animal menstrual dysmenorrhea model and application, wherein the animal with removed ovaries is injected with estrogen, progesterone and oxytocin, the pharmacological injection of progesterone can reduce the harm and mortality rate of the animal caused by the implantation and removal of a progesterone release body in the prior art, the surgical stress of the animal is reduced, the injection time of the progesterone in the application is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with the non-menstrual process of the dysmenorrhea model in the prior art, the animal menstrual dysmenorrhea model can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment, and effectively help patients to relieve pain.
Owner:HUNAN UNIV OF CHINESE MEDICINE

A method for detecting steroid hormones in serum

The present invention relates to a method for detecting steroid hormones in serum, comprising the following steps: (1) adding 0.1 to 20 mg of a magnetic solid phase extractant to each milliliter of a sample to be tested, mixing, magnetically separating, and removing liquid; adding a washing solution, mixing, magnetically separating, and removing liquid; adding an eluent for elution, mixing, magnetically separating, and collecting the eluent to obtain a test solution; (2) detecting the hormone content in the test solution by liquid chromatography and tandem mass spectrometry; wherein the hormone is selected from any one of testosterone, androstenedione, dihydrotestosterone, dehydroepiandrosterone sulfate, and 17α-hydroxyprogesterone or a combination thereof; the magnetic solid phase extractant comprises a magnetic core ferrosoferric oxide, a middle layer structure silica wrapping the magnetic core, and an outer layer mesoporous structure, wherein the outer layer mesoporous structure is selected from any one of polystyrene and polystyrene divinylbenzene or a combination thereof. The present invention has the characteristics of good stability, high accuracy and sensitivity, strong specificity, high recovery rate, simple and controllable operation, fast analysis speed, etc., and can be used for simultaneous quantitative detection of multiple hormones in clinical practice.
Owner:知孔(上海)科技发展有限公司

Use of ethinylestradiol and drospirenone for the preparation of a medicament for the treatment of post-traumatic stress disorder

PendingCN122351259ADrospirenoneOral contraceptive drug
This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.
Owner:WOMEN S HOSPITAL ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE

Microsphere composition for contraceptive microneedle and contraceptive microneedle comprising same

PendingCN120204158AOrganic active ingredientsMicroneedlesMicrosphereContragestazol
The invention provides a microsphere composition for a contraceptive microneedle and the contraceptive microneedle containing the composition. The microsphere composition for the contraceptive microneedle comprises one selected from the group consisting of sustained-release estrogen microspheres, sustained-release progesterone microspheres and mixtures thereof, and the sustained-release estrogen microspheres comprise 400-600 parts by weight of biodegradable polymer per 100 parts by weight of estrogen, every 100 parts by weight of progesterone and hydroxypropyl-beta-cyclodextrin (HP [beta] CD) in the sustained-release progesterone microspheres comprise 700-900 parts by weight of a biodegradable polymer, and the molar ratio of the progesterone to the hydroxypropyl-beta-cyclodextrin is (1: 2)-(1: 3). The microsphere composition for a contraceptive microneedle according to the present invention can stably encapsulate a drug, exhibits a sustained-release drug effect for at least one week, and has a particle size (Dv90) suitable for a microneedle. According to the contraceptive microneedle or the contraceptive microneedle patch, administration is convenient, the contraceptive microneedle or the contraceptive microneedle patch is used once a week, the transdermal medicine permeability is good, the short attachment time is allowed, and the medicine is slowly released for at least one week.
Owner:SMALLLAB

Application of matrine combined with medroxyprogesterone acetate in preparation of antitumor drugs

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of matrine combined with medroxyprogesterone acetate in preparation of antitumor drugs. According to the invention, matrine and medroxyprogesterone are combined for use, and the matrine and medroxyprogesterone are used for developing products such as drugs, preparations, kits and the like for treating endometrial cancer. Experimental results prove that after sophocarpidine and medroxyprogesterone acetate are combined for medication, the composition shows relatively strong activity of inhibiting endometrial cancer and relatively good synergistic inhibition effect, so that the composition has relatively good practical application value. Experimental results prove that the dosages of the two can be remarkably reduced after drug combination, and the anti-tumor effect is remarkably improved. Animal experiments show that in-vivo anti-tumor effects of sophocarpidine and medroxyprogesterone acetate can be improved by combined medication compared with that of single medication. In conclusion, the combined medication of the matrine and the medroxyprogesterone can become a new method for treating endometrial cancer patients.
Owner:HENAN UNIVERSITY

Application of hydroxyprogesterone caproate in enhancing tumor treatment effect

A method for co-administrating hydroxyprogesterone caproate, tyrosine kinase inhibitor, and / or anti-PD-I / PD-LI an-1 tibodies for tumor treatment. The present application also provides a corresponding pharmaceutical use and a pharmaceutical product. Co-administration with hydroxyprogesterone caproate can further improve the therapeutie effect of lenvatinib and anti-PD-I / PD-L1 antibodies against tumors.
Owner:SHENZHEN EVERGREEN THERAPEUTICS CO LTD

Formulation of long-acting levonorgestrel butanoate injectable depot suspension

An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin / progesterone-sensitive reproductive tract dysfunctions and disorders.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL

Progestin / testosterone transdermal gel

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.
Owner:POPULATION COUNCIL INC +1

Formulation of long-acting levonorgestrel butanoate injectable depot suspension

An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin / progesterone-sensitive reproductive tract dysfunctions and disorders.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL

Systems and methods for tracking progesterone

PendingUS20260070053A1Analysis material containersMaterial analysisObstetricsProgesterone metabolism
Embodiments of the invention comprise a test strip configured to detect one or more metabolites of progesterone in urine, and optionally further detect one or more additional metabolites or hormones in urine within the same test strip. Embodiments of the invention are methods of utilizing such a test strip in association with avoidance of pregnancy, detection of menopause, and in association with fertility planning purposes. Embodiments of the invention are associated with the incorporation of a test strip within a testing kit, optionally further comprising a digital reader.
Owner:MFB FERTILITY INC

System and method for predicting polycystic ovarian morphology (PCOM)

PCT designated stage expiredWO2024229877A1Health-index calculationMedical automated diagnosisOvarian morphologyPhysiology
A system and method for predicting polycystic ovarian morphology (PCOM), which predict the conditions of polycystic ovarian morphology of polycystic ovary syndrome patients by means of the level of testosterone (T), the level of 11-ketoandrostenedione (11KA4), the level of androstenedione (A4) and the level of 17OH-progesterone (17OHP), or by means of the level of anti-mullerian hormone (AMH), the level of testosterone (T) and age. Therefore, the present invention achieves accurate prediction of polycystic ovarian morphology, thus helping to understand causes of PCOM, facilitating typing diagnosis of PCOS, and assisting in determining the severity of the PCOS phenotypic spectrum.
Owner:PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg / kg to 18 mg / kg, preferably 8 to 12 mg / kg, more preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.
Owner:IMMUNOMEDICS INC

Method for treatment of malignant tumors of embryonic type

ActiveRU2865852C1Progestin AntagonistPR - Progesterone receptor
FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex
Owner:ХАНКИН СЕРГЕЙ ЛЕОНИДОВИЧ

Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof

Provided in the present invention is a pharmaceutical composition comprising hydroxyprogesterone caproate and an additional therapeutic agent for treating tumors, wherein the additional therapeutic agent is preferably a monoclonal antibody against PD-1 or PD-L1. Further provided in the present invention are a method for increasing the number of tumor infiltrating lymphocytes (TIL) as required and a method for treating cancers in a subject in need thereof, which comprises providing the hydroxyprogesterone caproate to the subject.
Owner:SHENZHEN EVERGREEN THERAPEUTICS CO LTD

Contraceptive compositions and methods for improved efficacy and modulation of side effects

Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at least part of the progestin from SHBG in the blood plasma, thereby increasing its bioavailability. Also disclosed are methods to modulate progestin and estrogen levels in the blood through the use of SHBG binding and displacement, to optimize the effectiveness of formulations for contraception and minimize the side effects and adverse events.
Owner:AGILE THERAPEUTICS INC

Progestin / Testosterone Transdermal Gel

PendingUS20260069607A1Organic active ingredientsAerosol deliverySide effectContragestazol
The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.
Owner:POPULATION COUNCIL INC +1

Synthesis of a potent aromatase inhibitor 17α-acetoxy-10β,11β-dihydroxy-progesterone for the treatment of ER+ breast cancer

Biotransformation of gestonorone acetate (1) with Cunninghamella blakesleeana (ATCC 8688) yielded a new analogue, 17α-actoxy-10β,11β-dihydroxy-progesterone (2). Compound 2 was identified as non-cytotoxic inhibitor of human aromatase enzyme (IC50=0.827±0.066 μM). Compound 2 showed a significant aromatase inhibitory activity, as compared to the standard aromatase inhibitory drug, exemestane (IC50=0.232±0.03 μM).
Owner:HEJ RES INST OF CHEM

Levonorgestrel long-acting slow-release implant and preparation method thereof

The invention relates to the technical field of contraceptives, and discloses a levonorgestrel long-acting slow-release implant and a preparation method thereof, the levonorgestrel long-acting slow-release implant comprises the following components by mass: 10-20 parts of a levonorgestrel bulk drug, 25-35 parts of PCL, 40-50 parts of PLGA, 3-8 parts of a solid dispersant, and 3-8 parts of an injection solvent. According to the invention, a composite structure of a levonorgestrel microcrystalline core with a particle size of 5-20 [mu] m and a PLGA-PCL gradient degradation coating is adopted, and an injection solvent is mixed to form a minimally invasive injection suspension; the preparation method comprises the following steps: preparing microcrystals through anti-solvent precipitation, preparing a gradient coating through fluidized bed coating, and mixing to prepare a suspension, thereby obtaining the levonorgestrel long-acting slow-release implant. After being subjected to hypodermic injection through a 27G narrow needle, the nanomaterial is self-assembled into a 3mm columnar solid, can be completely degraded into CO2 and H2O, and has long-term effectiveness, minimally invasive property, degradability and drug release stability.
Owner:HAINAN VOCATIONAL COLLEGE OF SCI & TECH

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg / kg to 18 mg / kg, preferably 8 to 12 mg / kg, more preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.
Owner:IMMUNOMEDICS INC

Contraceptive kit comprising oral dosage units containing dehydroepiandrosterone

PCT designated stageWO2025172590A1Organic active ingredientsSexual disorderPhysiologyIUD with progestogen
The invention relates to a contraceptive kit comprising: · 23 to 25 first oral dosage units, each first oral dosage unit containing a combination of 100-165 µg of levonorgestrel, 20-40 µg of ethinylestradiol and 40-120 mg of dehydroepiandrosterone; and · 3 to 5 second oral dosage units, each second oral dosage unit containing 40-120 mg of dehydroepiandrosterone, no progestogen and no estrogen; wherein the sum of the number of first oral dosage unit and the number of second oral dosage units in the contraceptive kit equals 28. The contraceptive kit of the invention provides high contraceptive reliability and produces less undesirable side-effects than commercially available combined oral contraceptives.
Owner:PANDORA ENDOCRINE INNOVATION BV

Method for evaluating urine of a subject to estimate the fertile window by evaluating for the presence of analytes of estrogen and progesterone

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and / or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and / or luteinizing hormone.
Owner:MFB FERTILITY INC

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg / kg to 18 mg / kg, preferably 8 to 12 mg / kg, more preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.
Owner:IMMUNOMEDICS INC

Dissociation liquid, kit and detection method for detecting progesterone in serum

The invention belongs to the technical field of sex hormone detection, and particularly relates to a dissociation liquid, a kit and a detection method for detecting progesterone in serum, the dissociation liquid comprises a buffer solution, a dissociation agent and a first preservative; wherein mestanolone and / or dihydrotestosterone is selected as the dissociation agent. Detection is carried out after a progesterone serum sample is treated with the dissociation liquid, the detection value and the sample value are not greatly different, and the dissociation liquid has high accuracy and sensitivity.
Owner:CHONGQING XINSAIYA BIOTECHNOLOGY CO LTD